{"doi":"10.1345/aph.19383","title":"Docetaxel as an Alternative to Paclitaxel after Acute Hypersensitivity Reactions","abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:</jats:title>\n                    <jats:p>To review the mechanism involved in paclitaxel-induced hypersensitivity reactions and to evaluate the potential use of docetaxel after acute hypersensitivity reactions (HSRs) to paclitaxel.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:</jats:title>\n                    <jats:p>Literature identified through a MEDLINE search (1966–September 2000) and through secondary sources.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:</jats:title>\n                    <jats:p>HSRs to paclitaxel can be life-threatening. The exact etiology involved in paclitaxel-induced HSRs has not been fully elucidated; the reactions may be due to the Cremophor EL vehicle or to paclitaxel itself. Options for treatment following HSRs are limited. A rechallenge attempt can be made, but is not always successful. Docetaxel, a semisynthetic taxane, may have a role in therapy for patients unable to tolerate paclitaxel therapy. This review examines the etiology of paclitaxel-induced HSRs and the potential role of docetaxel following these acute reactions.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:</jats:title>\n                    <jats:p>Docetaxel may be a viable alternative for patients who experience HSRs to paclitaxel.</jats:p>\n                  </jats:sec>","journal":"Annals of Pharmacotherapy","year":2000,"id":604613,"datarank":2.356224493723098,"base_score":3.5263605246161616,"endowment":3.5263605246161616,"self_citation_contribution":0.5289540786924243,"citation_network_contribution":1.8272704150306738,"self_endowment_contribution":0.5289540786924243,"citer_contribution":1.8272704150306738,"corpus_percentile":null,"corpus_rank":null,"citation_count":33,"citer_count":33,"citers_with_citation_signal":28,"citers_with_endowment":28,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1551335,"name":"Bridget J Bernstein","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Docetaxel as an Alternative to Paclitaxel after Acute Hypersensitivity Reactions","abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:</jats:title>\n                    <jats:p>To review the mechanism involved in paclitaxel-induced hypersensitivity reactions and to evaluate the potential use of docetaxel after acute hypersensitivity reactions (HSRs) to paclitaxel.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:</jats:title>\n                    <jats:p>Literature identified through a MEDLINE search (1966–September 2000) and through secondary sources.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:</jats:title>\n                    <jats:p>HSRs to paclitaxel can be life-threatening. The exact etiology involved in paclitaxel-induced HSRs has not been fully elucidated; the reactions may be due to the Cremophor EL vehicle or to paclitaxel itself. Options for treatment following HSRs are limited. A rechallenge attempt can be made, but is not always successful. Docetaxel, a semisynthetic taxane, may have a role in therapy for patients unable to tolerate paclitaxel therapy. This review examines the etiology of paclitaxel-induced HSRs and the potential role of docetaxel following these acute reactions.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:</jats:title>\n                    <jats:p>Docetaxel may be a viable alternative for patients who experience HSRs to paclitaxel.</jats:p>\n                  </jats:sec>","is_dataset_classified":null,"base_score":3.5263605246161616,"endowment":3.5263605246161616,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"11098349","pmcid":null,"openalex_id":"https://openalex.org/W2132924838","authors":[],"funders":[],"total_grants":0,"fwci":1.4484,"citation_percentile":0.83868999,"influential_citations":0,"citation_trend":[{"year":2012,"count":1},{"year":2013,"count":1},{"year":2014,"count":1},{"year":2016,"count":1},{"year":2017,"count":1},{"year":2019,"count":2},{"year":2021,"count":1},{"year":2024,"count":1}],"oa_status":"closed","license":"https://journals.sagepub.com/page/policies/text-and-data-mining-license","oa_locations":[{"url":"https://journals.sagepub.com/doi/pdf/10.1345/aph.19383","host_type":"publisher"},{"url":"https://doi.org/10.1345/aph.19383","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/11098349","host_type":"repository"}],"fields_of_study":["Drug-Induced Adverse Reactions","Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","Food Allergy and Anaphylaxis Research"],"mesh_terms":["Docetaxel","Adult","Aged","Antineoplastic Agents, Phytogenic","Clinical Trials as Topic","Drug Hypersensitivity","Female","Humans","Lung Neoplasms","Middle Aged","Ovarian Neoplasms","Paclitaxel","Taxoids"],"keywords":["Docetaxel","Paclitaxel","Medicine","Taxane","Hypersensitivity reaction","Chemotherapy","Etiology","Oncology","Pharmacology","Internal medicine","Cancer","Breast cancer"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T00:30:54.174786Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}